These active ingredients have previously been patented in separate medical products. The generic producers would need a license from the patent holder(s) for all of these ingredients for production and sale of the new FDC. The owner of a patent on a pharmaceutical active ingredient may choose not to license the invention to any third party to remain the only supplier on the market for that active ingredient.